BillionToOne: 3 Key Takeaways for Long-Term Investors
Key PointsBillionToOne raised 2026 revenue guidance to $460 million to $470 million.
Three key insights emerge from BillionToOne's (BLLN) earnings call on November 4, 2026. Firstly, the company raised its 2026 revenue guidance to between $460 million and $470 million, reflecting 47% year-over-year revenue growth to $123 million. This represents five consecutive quarters of positive GAAP operating income. Secondly, BillionToOne plans to launch Northstar Clear, a tissue-free minimal residual disease (MRD) test, on December 15, 2026.
This test offers several advantages over traditional tissue-dependent assays, including faster results and lower failure rates. Lastly, the company's gross margin reached 71% in the third quarter, driven by cost savings from software automation and high test throughput. These factors have enabled BillionToOne to achieve GAAP profitability and cash flow positivity, with a fraction of the accumulated deficit compared to its public peers.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
